[go: up one dir, main page]

MX2015012114A - Fabricacion continua integrada de principios activos proteinicos terapeuticos. - Google Patents

Fabricacion continua integrada de principios activos proteinicos terapeuticos.

Info

Publication number
MX2015012114A
MX2015012114A MX2015012114A MX2015012114A MX2015012114A MX 2015012114 A MX2015012114 A MX 2015012114A MX 2015012114 A MX2015012114 A MX 2015012114A MX 2015012114 A MX2015012114 A MX 2015012114A MX 2015012114 A MX2015012114 A MX 2015012114A
Authority
MX
Mexico
Prior art keywords
therapeutic proteins
continuous purification
drug substance
therapeutic protein
protein drug
Prior art date
Application number
MX2015012114A
Other languages
English (en)
Inventor
Konstantin Konstantinov
Veena Warikoo
Rahul Godawat
Sujit Jain
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of MX2015012114A publication Critical patent/MX2015012114A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1807—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using counter-currents, e.g. fluidised beds
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/10—Selective adsorption, e.g. chromatography characterised by constructional or operational features
    • B01D15/18—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns
    • B01D15/1864—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns
    • B01D15/1871—Selective adsorption, e.g. chromatography characterised by constructional or operational features relating to flow patterns using two or more columns placed in series
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/34—Size-selective separation, e.g. size-exclusion chromatography; Gel filtration; Permeation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction, e.g. ion-exchange, ion-pair, ion-suppression or ion-exclusion
    • B01D15/361—Ion-exchange
    • B01D15/363—Anion-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G or L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 and B01D15/30 - B01D15/36, e.g. affinity, ligand exchange or chiral chromatography
    • B01D15/3804—Affinity chromatography
    • B01D15/3814—Affinity chromatography of the substrate or cofactor-enzyme type
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/42—Selective adsorption, e.g. chromatography characterised by the development mode, e.g. by displacement or by elution
    • B01D15/422—Displacement mode
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/18—Ion-exchange chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M23/00—Constructional details, e.g. recesses, hinges
    • C12M23/52—Mobile; Means for transporting the apparatus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/10—Separation or concentration of fermentation products
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12M—APPARATUS FOR ENZYMOLOGY OR MICROBIOLOGY; APPARATUS FOR CULTURING MICROORGANISMS FOR PRODUCING BIOMASS, FOR GROWING CELLS OR FOR OBTAINING FERMENTATION OR METABOLIC PRODUCTS, i.e. BIOREACTORS OR FERMENTERS
    • C12M47/00—Means for after-treatment of the produced biomass or of the fermentation or metabolic products, e.g. storage of biomass
    • C12M47/12—Purification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2465—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1) acting on alpha-galactose-glycoside bonds, e.g. alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/005—Glycopeptides, glycoproteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01022—Alpha-galactosidase (3.2.1.22)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/01045—Glucosylceramidase (3.2.1.45), i.e. beta-glucocerebrosidase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Sustainable Development (AREA)
  • General Chemical & Material Sciences (AREA)
  • Clinical Laboratory Science (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Este documento contiene los procesos continuos e integrados de biofabricación para producir un principio activo proteínico terapéutico. Aquí contenidos también están los sistemas capaces de producir de manera continua un principio activo proteínico terapéutico.
MX2015012114A 2013-03-08 2014-03-03 Fabricacion continua integrada de principios activos proteinicos terapeuticos. MX2015012114A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361775060P 2013-03-08 2013-03-08
US201361856390P 2013-07-19 2013-07-19
PCT/US2014/019909 WO2014137903A2 (en) 2013-03-08 2014-03-03 Integrated continuous manufacturing of therapeutic protein drug substances

Publications (1)

Publication Number Publication Date
MX2015012114A true MX2015012114A (es) 2016-01-12

Family

ID=50424717

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2015012114A MX2015012114A (es) 2013-03-08 2014-03-03 Fabricacion continua integrada de principios activos proteinicos terapeuticos.
MX2020001823A MX2020001823A (es) 2013-03-08 2015-09-08 Fabricacion continua integrada de principios activos proteinicos terapeuticos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020001823A MX2020001823A (es) 2013-03-08 2015-09-08 Fabricacion continua integrada de principios activos proteinicos terapeuticos.

Country Status (15)

Country Link
US (6) US9650412B2 (es)
EP (1) EP2964663A2 (es)
JP (2) JP6608705B2 (es)
KR (1) KR102257356B1 (es)
CN (2) CN118388581A (es)
AU (4) AU2014226126B2 (es)
BR (1) BR112015021495A2 (es)
CA (1) CA2902854C (es)
HK (1) HK1219964A1 (es)
IL (2) IL274646B (es)
MX (2) MX2015012114A (es)
RU (2) RU2768003C2 (es)
SG (3) SG10201709131UA (es)
TW (3) TWI879787B (es)
WO (1) WO2014137903A2 (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799273B2 (en) 2004-05-06 2010-09-21 Smp Logic Systems Llc Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US10980244B2 (en) 2008-11-04 2021-04-20 The Quaker Oats Company Whole grain composition comprising hydrolyzed starch
US10689678B2 (en) 2008-11-04 2020-06-23 The Quaker Oats Company Method and composition comprising hydrolyzed starch
WO2012128881A1 (en) 2011-03-21 2012-09-27 Pepsico, Inc. Method for preparing high acid rtd whole grain beverages
BR112014002956A8 (pt) 2011-07-12 2022-09-06 Pepsico Inc Método de preparar uma bebida láctea contendo aveia
WO2014004103A1 (en) * 2012-06-29 2014-01-03 Emd Millipore Corporation Methods for inactivating viruses during a protein purification process
EP3460049A1 (en) 2013-02-22 2019-03-27 Genzyme Corporation Microcarrier perfusion culturing methods and uses thereof
HK1219751A1 (zh) 2013-02-22 2017-04-13 Genzyme Corporation 微载体灌注培养方法及其用途
RU2768003C2 (ru) 2013-03-08 2022-03-22 Джензим Корпорейшн Интегрированное непрерывное производство терапевтических белковых лекарственных веществ
TW202332774A (zh) 2013-10-23 2023-08-16 美商健臻公司 重組醣蛋白及其用途
US20160298072A1 (en) 2013-11-20 2016-10-13 Cmc Biologics A/S A bioreactor system and method for producing a biopol ymer
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
EP3102934B1 (en) 2014-02-07 2025-07-16 CMC Biologics A/S A chromatography system and method for capturing a biopolymer
US10844345B2 (en) 2014-04-16 2020-11-24 Cmc Biologics A/S High density fill and draw fermentation process
TW202204596A (zh) 2014-06-06 2022-02-01 美商健臻公司 灌注培養方法及其用途
TWI776235B (zh) 2014-06-09 2022-09-01 美商健臻公司 種子罐培養法(seed train processes)及其用途
AR102198A1 (es) 2014-10-09 2017-02-08 Regeneron Pharma Proceso para reducir partículas subvisibles en una formulación farmacéutica
WO2016064846A1 (en) 2014-10-24 2016-04-28 Genzyme Corporation Integrated continuous isolation of fluid streams from sterile process vessels
WO2016106291A1 (en) * 2014-12-22 2016-06-30 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
MX383857B (es) 2014-12-22 2025-03-14 Genzyme Corp Métodos de cultivo de una célula de mamífero.
US11571635B2 (en) * 2015-03-31 2023-02-07 Cytiva Sweden Ab Liquid chromatography system, a device, and a method
EP3015542A1 (de) 2015-05-07 2016-05-04 Bayer Technology Services GmbH Modulare anlage und verfahren zur kontinuierlichen, keimreduzierten produktion und/oder aufbereitung eines produktes
EP3037513A1 (de) * 2015-05-13 2016-06-29 Bayer Technology Services GmbH Verfahren zur kontinuierlichen elution eines produktes von chromatographiesäulen
EP3093335A1 (de) * 2015-05-13 2016-11-16 Bayer Technology Services GmbH Prozessleitsystem zur regelung und steuerung einer modular aufgebauten anlage zur produktion von biopharmazeutischen und biologischen makromolekularen produkten
JP2018532429A (ja) * 2015-10-26 2018-11-08 ロンザ リミテッド バイオ医薬品を生産するための製造設備
JP6878762B2 (ja) * 2015-12-18 2021-06-02 ウシオ電機株式会社 光照射装置及び光照射方法
US20170275662A1 (en) * 2016-03-22 2017-09-28 The Quaker Oats Company Method and Apparatus for Controlled Hydrolysis
US11172695B2 (en) 2016-03-22 2021-11-16 The Quaker Oats Company Method, apparatus, and product providing hydrolyzed starch and fiber
CA3021070A1 (en) 2016-04-14 2017-10-19 Trizell Ltd. Fixed-bed bioreactor with constant-flow pump/tubing system
LT3722435T (lt) * 2016-04-14 2025-10-10 Fiksuoto lovio bioreaktorius su nuolatinio srauto siurbliu / vamzdžių sistema
CN119119244A (zh) 2016-08-16 2024-12-13 里珍纳龙药品有限公司 用于对混合物中的个体抗体进行量化的方法
AU2017313042A1 (en) * 2016-08-16 2019-04-04 Genzyme Corporation Methods of processing a fluid including a recombinant therapeutic protein and use thereof
WO2018044699A1 (en) 2016-08-27 2018-03-08 3D Biotek, Llc Bioreactor
PL3500586T3 (pl) * 2016-10-17 2021-09-27 Enzene Biosciences Ltd. Sposób ciągły zmniejszania heterogeniczności białka terapeutycznego
KR102564393B1 (ko) 2016-10-25 2023-08-08 리제너론 파아마슈티컬스, 인크. 크로마토그래피 데이터 분석을 위한 방법 및 시스템
BE1024230B1 (fr) 2016-11-08 2017-12-20 Univercells Sa Production contenue de cellules et/ou de produits cellulaires
WO2018096054A1 (en) * 2016-11-24 2018-05-31 Alveolix Ag Cell culturing system and method
JP2020503900A (ja) 2017-01-10 2020-02-06 アミカス セラピューティックス インコーポレイテッド ファブリー病の処置のための組換えアルファ−ガラクトシダーゼａ
JP7171058B2 (ja) * 2017-02-21 2022-11-15 サイティバ・スウェーデン・アクチボラグ クロマトグラフィーシステムにおけるｕｖセル光路長の適合方法
EP3381529A1 (fr) 2017-03-29 2018-10-03 EMD Millipore Corporation Installation de traitement de liquide biologique
EP3381530A1 (fr) 2017-03-29 2018-10-03 EMD Millipore Corporation Installation de traitement de liquide biologique
US20200251186A1 (en) * 2017-04-01 2020-08-06 Massachusetts Institute Of Technology Systems and methods for using behavior data of impurities and target proteins to design downstream processes
CN111050887A (zh) 2017-08-31 2020-04-21 麻省理工学院 用于制造生物学地产生之产物的中空纤维膜过滤系统和方法
WO2019055796A1 (en) * 2017-09-15 2019-03-21 Bristol-Myers Squibb Company ONLINE BIOMASS CAPACITY MONITORING DURING LARGE SCALE PRODUCTION OF POLYPEPTIDES OF INTEREST
IL272954B2 (en) 2017-09-19 2024-06-01 Regeneron Pharma Methods of reducing particle formation and compositions formed thereby
WO2019060837A1 (en) * 2017-09-25 2019-03-28 Enzyvant Farber Gmbh PROCESS FOR PRODUCING RECOMBINANT HUMAN ACID CERAMIDASE
IL273549B2 (en) 2017-10-06 2023-10-01 Lonza Ag Automated control of cell culture using Raman spectroscopy
AU2018350898B9 (en) * 2017-10-16 2024-07-25 Regeneron Pharmaceuticals, Inc. Perfusion bioreactor and related methods of use
CN108101981B (zh) * 2018-01-15 2019-06-04 四川远大蜀阳药业有限责任公司 一种静注免疫球蛋白的生产工艺
WO2019150192A1 (en) * 2018-02-02 2019-08-08 Enzyvant Therapeutics Gmbh Methods for treating farber disease
CN119971563A (zh) 2018-03-02 2025-05-13 建新公司 用于生物制造的多元谱分析与监测
WO2019191133A1 (en) * 2018-03-27 2019-10-03 Bristol-Myers Squibb Company Real-time monitoring of protein concentration using ultraviolet signal
EP3546475A1 (en) 2018-03-27 2019-10-02 Sanofi Full flow-through process for purifying recombinant proteins
JP2021519590A (ja) * 2018-03-30 2021-08-12 アレクシオン ファーマシューティカルズ， インコーポレイテッド 糖タンパク質の製造
US12071607B2 (en) * 2018-06-01 2024-08-27 Lonza Ltd. Midscale model for organic growth and phasing
US10792618B2 (en) 2018-06-19 2020-10-06 Sartorius Stedim Biotech Gmbh Particle separation and/or purification of a fluid
TWI853823B (zh) 2018-07-02 2024-09-01 美商里珍納龍藥品有限公司 自混合物製備多肽之系統及方法
JP7063759B2 (ja) * 2018-07-25 2022-05-09 株式会社日立プラントサービス 精製装置
WO2020033867A2 (en) 2018-08-10 2020-02-13 Alexion Pharmaceuticals, Inc. Methods of treating neurofibromatosis type 1 and related conditions with alkaline phosphatase
US12172108B2 (en) 2018-08-16 2024-12-24 Emd Millipore Corporation Closed bioprocessing device
KR102824467B1 (ko) 2018-08-31 2025-06-26 젠자임 코포레이션 멸균 크로마토그래피 수지 및 제조 공정에서 이의 용도
CN111184636A (zh) * 2018-11-14 2020-05-22 正大天晴药业集团南京顺欣制药有限公司 含重组蛋白的药物组合物的制备
AU2019423931B2 (en) * 2019-01-25 2025-06-05 Enzene Biosciences Limited Automated integrated continuous system and bioprocess for producing therapeutic protein
NZ777640A (en) * 2019-02-15 2025-11-28 Merck Sharp & Dohme Automated biomanufacturing systems, facilities, and processes
JP7704679B2 (ja) * 2019-02-15 2025-07-08 ジャスト－エヴォテック バイオロジクス，インコーポレイテッド 生物学的治療薬製造施設とプロセス
JP6857334B2 (ja) * 2019-03-27 2021-04-14 ウシオ電機株式会社 光照射装置
JP6763450B2 (ja) * 2019-03-27 2020-09-30 ウシオ電機株式会社 光照射装置
US12509655B2 (en) 2019-04-01 2025-12-30 Boehringer Ingelheim International Gmbh Integrated and continuous recombinant protein manufacturing
MX2021012078A (es) * 2019-04-03 2022-01-04 Genzyme Corp Produccion continua de proteinas recombinantes.
GB201908612D0 (en) * 2019-06-17 2019-07-31 Ge Healthcare Bio Sciences Ab A method for separating biomolecules
CN110348090B (zh) * 2019-06-28 2021-05-04 浙江大学 基于人工神经网络实现多柱连续流层析设计及分析的方法
CN110348089B (zh) * 2019-06-28 2021-05-04 浙江大学 基于层析模型实现多柱连续流层析设计及分析的方法
FR3099066B1 (fr) * 2019-07-26 2021-08-13 Novasep Process Procédé de purification d’une substance cible avec inactivation virale
GB201911686D0 (en) * 2019-08-15 2019-10-02 Fujifilm Diosynth Biotechnologies Uk Ltd Process for purifying target substances
AU2020343680A1 (en) * 2019-09-06 2022-03-24 Amicus Therapeutics, Inc. Method for capturing and purification of biologics
EP4034871A1 (en) * 2019-09-23 2022-08-03 Genzyme Corporation Product quality attribute measurement
KR20220082906A (ko) * 2019-10-22 2022-06-17 젠자임 코포레이션 통합형 연속 바이오-제조에서의 인라인 생성물 모니터링
EP4058547A1 (en) 2019-11-15 2022-09-21 Lonza Ltd. Process and system for producing an inoculum
CA3161266A1 (en) 2019-12-09 2021-06-17 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
GB202003336D0 (en) * 2020-03-06 2020-04-22 National Institute For Bioprocesisng Res And Training A system for producing a biopharmaceutical product
KR102370142B1 (ko) 2020-03-23 2022-03-04 프레스티지바이오로직스 주식회사 항체 의약품 제조를 위한 배양 및 정제 공정의 하이브리드 시스템
EP4026892A1 (en) 2021-01-12 2022-07-13 Sartorius Stedim Biotech GmbH Device assembly and method for controlling an integrated continuous pharmaceutical or biopharmaceutical manufacturing process
GB202101775D0 (en) * 2021-02-09 2021-03-24 Cytiva Sweden Ab Method in bioprocess purification system
US12083169B2 (en) 2021-02-12 2024-09-10 Alexion Pharmaceuticals, Inc. Alkaline phosphatase polypeptides and methods of use thereof
AU2022234768A1 (en) * 2021-03-10 2023-07-27 Amgen Inc. Methods for purification of recombinant proteins
KR20230170728A (ko) * 2021-04-14 2023-12-19 젠자임 코포레이션 포유류 세포의 관류 배양 방법
GB202109015D0 (en) * 2021-06-23 2021-08-04 Puridify Ltd A method for purifying a feed in a chromatography system
EP4401853A1 (en) * 2021-09-14 2024-07-24 Sanofi Chromatography system
US20230175633A1 (en) * 2021-12-02 2023-06-08 Whirlpool Corporation Insulated structures and methods of making the same
WO2023129541A2 (en) * 2021-12-28 2023-07-06 Mott Corporation Selectable media filter and sparger assemblies and related methods of fabrication and use
KR20240154657A (ko) 2022-03-07 2024-10-25 다케다 야쿠힌 고교 가부시키가이샤 임상 인간 igg 제품의 친화도 크로마토그래피 생산
EP4502169A4 (en) 2022-03-28 2025-12-31 Fujifilm Corp PRODUCT PRODUCTION PROCESS AND PRODUCT
EP4501335A4 (en) * 2022-03-30 2025-07-23 Fujifilm Corp METHOD FOR PRODUCING ACTIVE INGREDIENT OF BIOLOGICAL DRUG, SYSTEM FOR PRODUCING ACTIVE INGREDIENT OF BIOLOGICAL DRUG, AND ACTIVE INGREDIENT OF BIOLOGICAL DRUG
EP4501334A4 (en) * 2022-03-30 2025-07-16 Fujifilm Corp METHOD FOR THE MANUFACTURE OF A BIOPHARMACEUTICAL DRUG SUBSTANCE, SYSTEM FOR THE MANUFACTURE OF A BIOPHARMACEUTICAL DRUG SUBSTANCE, AND BIOPHARMACEUTICAL DRUG SUBSTANCE
WO2023247798A1 (de) 2022-06-24 2023-12-28 Bilfinger Life Science Gmbh Modulare vorrichtung und verfahren zur kontinuierlichen herstellung von biotechnologischen produkten
DE102022208467A1 (de) 2022-06-24 2024-01-04 Bilfinger Life Science Gmbh Modulare Vorrichtung und Verfahren zur kontinuierlichen Herstellung von biotechnologischen Produkten
KR20240039642A (ko) * 2022-09-19 2024-03-27 주식회사 녹십자 신규 헤파란-n-설파타아제의 정제 방법

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4401108A (en) 1980-02-13 1983-08-30 Thomas Jefferson University Radioactive material loading, calibration and injection systems
SU1033181A1 (ru) 1982-02-02 1983-08-07 Томское Отделение Охтинского Ордена Ленина И Ордена Трудового Красного Знамени Научно-Производственного Объединения "Пластполимер" Способ обработки полимерного сорбента дл хроматографии
JPS6075530A (ja) 1983-09-30 1985-04-27 Asahi Chem Ind Co Ltd 金属元素の新しい分離精製方法
US4559175A (en) 1984-04-19 1985-12-17 The United States Of America As Represented By The Secretary Of The Air Force Halo-substituted diphospha-s-triazines and their derivatives
US4885250A (en) 1987-03-02 1989-12-05 E. I. Du Pont De Nemours And Company Enzyme immobilization and bioaffinity separations with perfluorocarbon polymer-based supports
US5612016A (en) 1988-04-01 1997-03-18 Immunomedics, Inc. Conjugates of antibodies and bifunctional ligands
US5169936A (en) 1989-04-14 1992-12-08 Biogen, Inc. Protein purification on immobilized metal affinity resins effected by elution using a weak ligand
AU6355790A (en) 1989-08-04 1991-03-11 Peter Grandics An integrated cell culture-protein purification system for the automated production and purification of cell culture products
US5244816A (en) 1989-10-11 1993-09-14 Akzo N.V. Method for purifying chelator conjugated compounds
WO1992017403A1 (en) 1991-04-05 1992-10-15 Brigham Young University Support bonded polyalkylene-polyamine-poly(carboxylic acid) and extraction of metal ions therewith
RU2034853C1 (ru) 1992-07-14 1995-05-10 Научно-исследовательский институт строительных материалов при Томской государственной инженерно-строительной академии Способ получения полимерного сорбента для хроматографии
JP2871435B2 (ja) 1993-04-22 1999-03-17 イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー 親水性ポリマー被覆パーフルオロカーボンポリマーベースのマトリックスの製造方法
JPH07110229A (ja) 1993-10-12 1995-04-25 Nkk Corp 金属ストリップループの最下点位置検出装置
US5478924A (en) 1994-02-16 1995-12-26 Cramer; Steven M. Displacement chromatography of proteins using low molecular weight displacers
US5429746A (en) 1994-02-22 1995-07-04 Smith Kline Beecham Corporation Antibody purification
US5856179A (en) 1994-03-10 1999-01-05 Genentech, Inc. Polypeptide production in animal cell culture
US5423982A (en) * 1994-05-31 1995-06-13 Biosepra Inc. Liquid chromatography column adapted for in situ chemical sterilization
US5610285A (en) 1994-08-24 1997-03-11 Bayer Corporation Purification of α-1 proteinase inhibitor using novel chromatographic separation conditions
US6359114B1 (en) 1995-06-07 2002-03-19 Aphton Corp. System for method for the modification and purification of proteins
US5691152A (en) 1995-11-09 1997-11-25 E. R. Squibb & Sons, Inc. Stable avidin composition
AR005035A1 (es) 1995-12-11 1999-04-07 Merck Patent Ges Mit Beschränkter Haftung Procedimiento para preparar proteinas recombinantes en e. coli, mediante fermentacion con gran concentracion de celulas.
ATE371673T1 (de) 1996-11-27 2007-09-15 Genentech Inc Affinitätsreinigung von polypeptiden an einer protein a-matrix
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
US6955917B2 (en) 1997-06-20 2005-10-18 Bayer Healthcare Llc Chromatographic method for high yield purification and viral inactivation of antibodies
US6265542B1 (en) 1997-10-24 2001-07-24 Genentech, Inc. Purification of molecules
US7611831B2 (en) 1998-01-06 2009-11-03 Cerus Corporation Adsorbing pathogen-inactivating compounds with porous particles immobilized in a matrix
SI1308455T1 (sl) 1998-05-06 2006-08-31 Genentech Inc Sestavek, ki obsega protitelesa anti-HER2
DE19858892A1 (de) 1998-12-19 2000-06-21 Merck Patent Gmbh Kontinuierliches Verfahren zur Trennung von Stoffen nach Molekülgröße
GB9902000D0 (en) 1999-01-30 1999-03-17 Delta Biotechnology Ltd Process
GB0028879D0 (en) 2000-11-27 2001-01-10 Prometic Biosciences Ltd Adsorbents and their use
EE200300408A (et) 2001-02-23 2003-12-15 Immunex Corporation Aktiivsete valkude saagise suurendamine
ITBO20010426A1 (it) * 2001-07-06 2003-01-06 Alfa Wassermann Spa Processo per la purificazione di proteine farmacologicamente attive mediante cromatografia in scambio cationico
US7252799B2 (en) 2001-08-31 2007-08-07 Clearant, Inc. Methods for sterilizing preparations containing albumin
US20030095890A1 (en) 2001-09-24 2003-05-22 Shirley Miekka Methods for sterilizing biological materials containing non-aqueous solvents
AU2002343100A1 (en) 2001-11-27 2003-06-10 Prometic Biosciences Ltd. The use of metal-chelating adsorbents
US6660172B2 (en) 2002-01-31 2003-12-09 Koslow Technologies Corporation Precoat filtration media and methods of making and using
AU2003210802B2 (en) 2002-02-05 2009-09-10 Genentech Inc. Protein purification
KR100788093B1 (ko) 2002-04-26 2007-12-21 제넨테크, 인크. 단백질의 비친화성 정제
US6902909B2 (en) 2002-07-09 2005-06-07 Synthecon, Inc. Methods for efficient production of mammalian recombinant proteins
CA2496060C (en) 2002-09-11 2015-08-04 Genentech, Inc. Protein purification by ion exchange chromatography
CA2498725C (en) 2002-09-13 2014-07-08 Biogen Idec Inc. Method of purifying polypeptides by simulated moving bed chromatography
US7157276B2 (en) 2003-06-20 2007-01-02 Biogen Idec Inc. Use of depth filtration in series with continuous centrifugation to clarify mammalian cell cultures
US7750129B2 (en) 2004-02-27 2010-07-06 Ge Healthcare Bio-Sciences Ab Process for the purification of antibodies
ES2407380T5 (es) 2004-02-27 2017-07-07 Octapharma Ag Procedimiento para proporcionar una preparación de anticuerpos purificada, sin riesgo respecto a virus
EP1773976B2 (en) 2004-06-04 2020-01-01 Global Life Sciences Solutions USA LLC Disposable bioreactor systems and methods
US20060004621A1 (en) 2004-06-30 2006-01-05 Malek Kamal M Real-time selection of survey candidates
WO2006026248A1 (en) 2004-08-25 2006-03-09 Sigma-Aldrich Co. Compositions and methods employing zwitterionic detergent combinations
EP1807101B1 (en) 2004-09-30 2016-04-13 Bayer Healthcare LLC Devices and methods for integrated continuous manufacturing of biological molecules
WO2006039533A2 (en) 2004-09-30 2006-04-13 Sloan Kettering Institure For Cancer Research Bcr-abl imatinib resistance-associated peptides and methods of use thereof
AU2005296352B2 (en) 2004-10-21 2011-01-06 Cytiva Bioprocess R&D Ab Chromatography ligand
JP5553963B2 (ja) 2004-10-22 2014-07-23 アムジエン・インコーポレーテツド 組換え抗体をリフォールディングする方法
BRPI0518661A2 (pt) * 2004-12-22 2008-12-02 Ambrx Inc mÉtodos para expressço e purificaÇço do hormânio do crescimento humano recombinante
JP5021610B2 (ja) 2005-03-07 2012-09-12 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ 滅菌法
CN1923290A (zh) 2005-04-29 2007-03-07 成都夸常医学工业有限公司 一种病毒灭活方法、其中所用的处理系统以及装置
US8043833B2 (en) 2005-10-31 2011-10-25 Novo Nordisk A/S Expression of soluble therapeutic proteins
AU2006329963B2 (en) 2005-12-06 2011-06-09 Amgen Inc. Polishing steps used in multi-step protein purification processes
WO2007116322A2 (en) 2006-02-17 2007-10-18 Novartis Ag Purification of bacterial antigens
US7673757B2 (en) 2006-02-17 2010-03-09 Millipore Corporation Adsorbent filter media for removal of biological contaminants in process liquids
US8117924B2 (en) 2006-04-21 2012-02-21 Bayer Healthcare Llc Apparatus, system, and method for in-situ measurements
US20080132688A1 (en) 2006-09-22 2008-06-05 Amgen Inc. Methods for Removing Viral Contaminants During Protein Purification
US20080207487A1 (en) * 2006-11-02 2008-08-28 Neose Technologies, Inc. Manufacturing process for the production of polypeptides expressed in insect cell-lines
BRPI0721035A2 (pt) 2007-02-01 2014-07-29 Mallinckrodt Baker Inc Soluções de armazenamento de meios cromatográficos e de equipamento cromatográfico e uso das mesmas.
GB0704603D0 (en) 2007-03-09 2007-04-18 Ge Healthcare Bio Sciences Ab Packing system and method for chromatography columns
US9597610B2 (en) 2007-03-09 2017-03-21 Ge Healthcare Bioprocess R&D Ab Packing system and method for chromatography columns
US9012212B2 (en) * 2007-04-17 2015-04-21 Xendo Holding B.V. Method and device for continuous membrane adsorption
US7901581B2 (en) 2007-06-15 2011-03-08 Ge Healthcare Bio-Sciences Ab Chromatography method
US7809258B2 (en) 2007-07-06 2010-10-05 Flir Systems Ab Camera and method for use with camera
US9109193B2 (en) 2007-07-30 2015-08-18 Ge Healthcare Bio-Sciences Corp. Continuous perfusion bioreactor system
CN103554215B (zh) * 2007-10-30 2016-06-15 健泰科生物技术公司 通过阳离子交换层析进行的抗体纯化
KR20130133894A (ko) 2007-12-27 2013-12-09 오츠카 세이야쿠 가부시키가이샤 에쿠올 합성에 관여하는 효소
WO2009103791A1 (en) * 2008-02-22 2009-08-27 Genmab A/S Methods for assissing the risk of adverse events upon treatment with igg4 antibodies
JP5619738B2 (ja) * 2008-06-24 2014-11-05 オクタファルマ アクチェンゲゼルシャフト 凝固第ｖｉｉｉ因子の精製方法
TW201024318A (en) 2008-10-20 2010-07-01 Abbott Lab Isolation and purification of antibodies using protein A affinity chromatography
CN102271775A (zh) * 2008-12-08 2011-12-07 诺沃-诺迪斯克有限公司 多肽的逆流提纯
US8728479B2 (en) 2009-03-31 2014-05-20 The Trustees Of The University Of Pennsylvania Antigen-binding proteins comprising recombinant protein scaffolds
EP2236617A1 (en) 2009-03-31 2010-10-06 Leukocare Ag Methods of terminal sterilization of biofunctional compositions
WO2010149259A2 (en) 2009-06-22 2010-12-29 Merck Patent Gmbh Conducting formulation
US8580554B2 (en) 2009-07-31 2013-11-12 Baxter International Inc. Method of producing a polypeptide or virus of interest in a continuous cell culture
NZ599583A (en) 2009-10-29 2013-09-27 Ascendis Pharma As Sterilization of biodegradable hydrogels
WO2011078772A1 (en) 2009-12-22 2011-06-30 Ge Healthcare Bio-Sciences Ab Method for dry packing chromatography columns
GB0922426D0 (en) 2009-12-22 2010-02-03 Ge Healthcare Bio Sciences Ab Containers for chromatography media
WO2011147762A2 (en) 2010-05-25 2011-12-01 Bayer Pharma Aktiengesellschaft Stabilized radiopharmaceutical composition
JP5932780B2 (ja) 2010-06-03 2016-06-08 ジーイー・ヘルスケア・バイオサイエンス・アクチボラグ クロマトグラフィーカラムモジュールの並列アセンブリ
WO2012049324A2 (en) 2010-10-15 2012-04-19 Straumann Holding Ag New emd formulation comprising pga
WO2012071135A2 (en) 2010-11-23 2012-05-31 Biovec Transfusion, Llc Methods for removing pathogens from a platelet preparation
WO2012073677A1 (ja) 2010-11-29 2012-06-07 三菱電機株式会社 レーザ加工機の光路構造
WO2012074481A1 (en) 2010-12-03 2012-06-07 Ge Healthcare Bio-Sciences Ab System and process for biopolymer chromatography
EP3578522A1 (en) 2010-12-06 2019-12-11 Pall Corporation Continuous processing methods for biological products
CN102321316B (zh) 2011-08-25 2013-04-24 上海恒方大高分子材料科技有限公司 一种适用于γ射线辐照消毒的医用PVC材料及其制备方法
WO2013045546A1 (de) 2011-09-30 2013-04-04 Bayer Intellectual Property Gmbh Homogene extrudierte artikel aus thermoplastisch verarbeitbaren polyurethanen auf basis von polyesterdiolen aus bernsteinsäure und 1,3 -propandiol
EP2656892A1 (en) 2012-04-23 2013-10-30 Merck Patent GmbH Chromatography method
US20140154270A1 (en) 2012-05-21 2014-06-05 Chen Wang Purification of non-human antibodies using kosmotropic salt enhanced protein a affinity chromatography
WO2014004103A1 (en) * 2012-06-29 2014-01-03 Emd Millipore Corporation Methods for inactivating viruses during a protein purification process
EP2682168A1 (en) * 2012-07-02 2014-01-08 Millipore Corporation Purification of biological molecules
CN105777862A (zh) * 2012-10-24 2016-07-20 建新公司 使用mes和mops作为流动相改性剂从多峰树脂洗脱生物分子
RU2768003C2 (ru) 2013-03-08 2022-03-22 Джензим Корпорейшн Интегрированное непрерывное производство терапевтических белковых лекарственных веществ
CN103223333B (zh) 2013-04-15 2015-01-14 河海大学 一种含双偕胺肟基的改性硅胶吸附剂及其制备方法
JP6653654B2 (ja) 2014-01-17 2020-02-26 レプリゲン・コーポレイションＲｅｐｌｉｇｅｎ Ｃｏｒｐｏｒａｔｉｏｎ クロマトグラフィーカラムの滅菌
TWI709569B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
US20240100450A9 (en) 2014-01-17 2024-03-28 Repligen Corporation Sterilizing chromatography columns
KR102586771B1 (ko) 2017-01-30 2023-10-11 리제너론 파마슈티칼스 인코포레이티드 크로마토그래피에서 바이오버든을 감소시키기 위한 조성물 및 방법
KR102824467B1 (ko) 2018-08-31 2025-06-26 젠자임 코포레이션 멸균 크로마토그래피 수지 및 제조 공정에서 이의 용도

Also Published As

Publication number Publication date
US20150232505A1 (en) 2015-08-20
US12110312B2 (en) 2024-10-08
IL274646A (en) 2020-06-30
TWI702226B (zh) 2020-08-21
AU2014226126B2 (en) 2019-02-14
IL274646B (en) 2022-09-01
KR102257356B1 (ko) 2021-05-31
AU2014226126A1 (en) 2015-10-01
TW201920230A (zh) 2019-06-01
CN118388581A (zh) 2024-07-26
WO2014137903A3 (en) 2014-10-30
AU2019203128A1 (en) 2019-05-30
TWI879787B (zh) 2025-04-11
CA2902854C (en) 2024-01-23
RU2018122100A3 (es) 2021-08-06
TW201518315A (zh) 2015-05-16
TWI659965B (zh) 2019-05-21
WO2014137903A2 (en) 2014-09-12
CA2902854A1 (en) 2014-09-12
TW202043252A (zh) 2020-12-01
US20150183821A1 (en) 2015-07-02
JP2016510981A (ja) 2016-04-14
SG10201709131UA (en) 2017-12-28
RU2015142657A (ru) 2017-04-13
KR20150125714A (ko) 2015-11-09
US9650413B2 (en) 2017-05-16
RU2018122100A (ru) 2019-03-12
JP6608705B2 (ja) 2019-11-20
IL240792A0 (en) 2015-10-29
AU2024213121A1 (en) 2024-09-12
US10711034B2 (en) 2020-07-14
AU2021200474A1 (en) 2021-02-25
US20200317726A1 (en) 2020-10-08
EP2964663A2 (en) 2016-01-13
BR112015021495A2 (pt) 2017-07-18
US20170218012A1 (en) 2017-08-03
AU2019203128B2 (en) 2020-10-29
MX2020001823A (es) 2020-07-13
RU2662929C2 (ru) 2018-07-31
CN105377874A (zh) 2016-03-02
US20240417427A1 (en) 2024-12-19
RU2768003C2 (ru) 2022-03-22
US9657056B2 (en) 2017-05-23
AU2021200474B2 (en) 2024-05-23
US9650412B2 (en) 2017-05-16
IL240792B (en) 2020-05-31
JP2020033364A (ja) 2020-03-05
SG11201506775VA (en) 2015-09-29
US20140255994A1 (en) 2014-09-11
HK1219964A1 (zh) 2017-04-21
SG10202011130TA (en) 2020-12-30

Similar Documents

Publication Publication Date Title
MX2020001823A (es) Fabricacion continua integrada de principios activos proteinicos terapeuticos.
ZA201508673B (en) Antibody locker for the inactivation of protein drug
PT3139986T (pt) Sistema para administração de gás terapêutico
EP3046603A4 (en) Fail-safe drug infusion therapy system
DK3328880T3 (da) Terapeutiske midler
PL3013416T3 (pl) Układy do przeprowadzania terapii za pomocą ambulatoryjnego urządzenia medycznego
EP3102097A4 (en) Body-worn system for continuous, noninvasive measurement of vital signs
IL253719A0 (en) Pharmaceutical compositions for combination therapy
DK3404106T3 (da) Ekspressionssystem til selektiv genterapi
HUE039864T2 (hu) Gyógyászati készítmények CFTR-közvetítette betegségek kezelésére
EP2978854A4 (en) Systems and methods for the targeted production of a therapeutic protein within a target cell
MY165759A (en) Pull-on diaper
PL2989110T3 (pl) Derywaty tamoxyfenu do leczenia chorób nowotworowych, szczególnie z wyższym poziomem białka her2
GB201312344D0 (en) Liposomal drug delivery system for bone cements
EP3062790A4 (en) Pharmaceutical combinations for the treatment of cancer
IL248779A0 (en) Pharmaceutical compositions for treating infectious diseases
EP3083695A4 (en) Anti-ron monoclonal antibodies as a cytotoxic drug delivery system for targeted cancer therapy
EP3046582A4 (en) Uses of modified mullerian inhibiting substance (mis) proteins for the treatment of neurodegenerative diseases
MX2015013066A (es) Usos terapéuticos para anticuerpos contra vegfr1.
EP3238754A4 (en) Blood purification system
MY167383A (en) Disposable diaper
EP3011941A4 (en) Medical pendant system
EP3351286A4 (en) DEVICE FOR THE ADMINISTRATION OF A MEDICAMENT SOLUTION
IL231498B (en) Compositions for the treatment of peripheral ulcers of various origins
EP3238755A4 (en) Solution producing device and blood purification system

Legal Events

Date Code Title Description
FG Grant or registration